Review

The Role of Incretin Therapy at Different Stages of Diabetes

Simona Cernea

Manuscript submitted June 27, 2011; resubmitted August 1, 2011; accepted August 10, 2011.

Keywords: type 2 diabetes, glycemic control, incretin, GLP-1, DPP-4, GIP, liraglutide, insulin

Abstract

The pathogenetic mechanisms causing type 2 diabetes are complex, and include a significant reduction of the incretin effect. In patients with type 2 diabetes, GLP-1 secretion may be impaired, while GIP secretion seems unaffected. In contrast, the insulinotropic activity of GIP is severely altered, whereas that of GLP-1 is maintained to a great extent. Better understanding of the role of incretin hormones in glucose homeostasis has led to the development of incretin-based therapies that complement and offer important advantages over previously used agents. Incretin-based agents have significant glucose-lowering effects, promote weight loss (or are weight-neutral), inhibit glucagon secretion while maintaining counter-regulatory mechanisms, exhibit cardiovascular benefits, and protect β-cells while possessing a low risk profile. At present, incretin-based therapies are most widely used as add on to metformin to provide sufficient glycemic control after metformin failure. However, they are also recommended as monotherapy early in the disease course, and later in triple combination. These agents may also be a promising therapeutic tool in prediabetic subjects. Therefore, a therapeutic algorithm is needed for their optimal application at different stages of diabetes, as suggested in this article.

Fulltext: HTML , PDF (262KB)

This article has been cited by other articles:

	Correlation Between Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in Italy Lapolla A, Frison V, Bettio M, Pos MD, Rocchini P, Panebianco G, Tadiotto F, Tos VD, D'Ambrosio M, Marangoni A, et al. Clin Ther 2015. pii:S0149-2918(14)00829-7
	Differential acute postprandial effects of processed meat and isocaloric vegan meals on the gastrointestinal hormone response in subjects suffering from type 2 diabetes and healthy controls: a randomized crossover study Belinova L, Kahleova H, Malinska H, Topolcan O, Vrzalova J, Oliyarnyk O, Kazdova L, Hill M, Pelikanova T Plos One 2014. 9(9):e107561
	Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies Shubrook JH Jr J Am Osteopath Assoc 2014. 114(5 Suppl 2):S6-S13
	Benefits of healthy adipose tissue in the treatment of diabetes Gunawardana SC World J Diabetes 2014. 5(4):420-430
	Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a randomized, double-blinded, and placebo-controlled trial. Liu CY, Huang CJ, Huang LH, Chen IJ, Chiu JP, Hsu CH Plos One 2014. 9(3):e91163
	Effect of combined therapy of human Wharton's jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats Hu J, Wang F, Sun R, Wang Z, Yu X, Wang L, Gao H, Zhao W, Yan S, Wang Y Endocrine 2014. 45(2):279-287
	Diabetes and beta cell function: from mechanisms to evaluation and clinical implications Cernea S, Dobreanu M Biochem Med (Zagreb) 2013. 23(3):266-280
	Adipose tissue, hormones, and treatment of type 1 diabetes Gunawardana SC Curr Diabetes Rep 2012. 12(5):542-550
	The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities Ostroukhova EN, Khmel'nitskii OK, Krasil'nikova EI, Davidenko KS Probl Endocrinol 2012. 58(3):51-55
	The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS Special Issue Raz I, Gallwitz B Rev Diabet Stud 2011. 8(3):288-292